To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
David W Cescon
MD, PhD
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Medical Oncologist and Clinician Scientist
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Associate Professor, Department of Medicine
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.
LEARNING OBJECTIVES
- Evaluate published research findings, clinical factors such as PD-L1, HER2 and BRCA status and patient preferences in the selection and sequencing of available therapeutic agents and strategies for newly diagnosed metastatic triple-negative breast cancer (mTNBC).
- Review published research supporting the use of antibody-drug conjugate therapy and anti-PD-1/PD-L1 antibodies for patients with mTNBC, and use this information to make appropriate treatment recommendations.
- Recognize the spectrum, frequency and severity of treatment-emergent adverse events associated with agents and approaches commonly used in the management of mTNBC, and develop strategies to monitor for, prevent and manage these complications.
- Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for mTNBC.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Cescon — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, GenomeRx, Gilead Sciences Inc, GSK, Knight Therapeutics Inc, Lilly, Merck, NeoGenomics, Novartis, Pfizer Inc, Roche Laboratories Inc, SAGADiagnostics; Contracted Research: AstraZeneca Pharmaceuticals LP, GenomeRx, Gilead Sciences Inc, Grail Inc GSK, Guardant Health, Knight Therapeutics Inc, Merck, NeoGenomics, Pear Bio, Pfizer Inc, ProteinQure, RayzeBio, Roche Laboratories Inc.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from Gilead Sciences Inc.
Release date: September 2026
Expiration date: September 2027
Caputo R et al. Real-world outcomes with sacituzumab govitecan in patients with triple-negative breast cancer and central nervous system metastases. San Antonio Breast Cancer Symposium 2025;Abstract PS5-03-15.
Gazzoni G et al. Intracranial activity of sacituzumab govitecan in HER2-negative breast cancer brain metastases: A systematic review and meta-analysis. ASCO 2026;Abstract e14009.
Ruicci KM et al. The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial. Clin Transl Radiat Oncol 2026;59:101164. Abstract
Rugo HS et al. KEYLYNK-009: Pembrolizumab plus olaparib in locally recurrent inoperable or metastatic triple-negative breast cancer after clinical benefit from first-line pembrolizumab plus chemotherapy. Clin Cancer Res 2026;32(5):883-93. Abstract
Rugo HS et al. Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. NPJ Breast Cancer 2026;[Online ahead of print].
Tarantino P et al. Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial. San Antonio Breast Cancer Symposium 2025;Abstract PS1-09-02.
von Kroge P et al. Brain metastases of a triple-negative breast cancer: A systematic literature review of the systemic treatment options. Breast Care (Basel) 2025;20(5):364-74. Abstract